One Lab Bench Built Six Complex Molecules From a Single Starting Point

The Strychnine Paradox Nobody Talks About

Strychnine is the molecule that broke chemistry. Not because it kills rats — though it does — but because building its tetracyclic cage from scratch took decades of brute force. In , a Princeton team did something stranger: they built six different alkaloids — strychnine, aspidospermidine, vincadifformine, akuammicine, kopsanone, and kopsinine — all from the same flat-ish precursor.

Here's why that matters. Most total syntheses are one-off masterpieces. You build molecule A with a clever trick; you can't reuse that trick for molecule B, because the stereochemistry, ring count, or functional groups don't line up. The MacMillan group flipped the whole thing: they designed an organocascade sequence so general that it funnels many starting materials into one common tetracyclic intermediate (compound ), then branches out to six distinct alkaloids.

What Cascade Catalysis Actually Does to a Molecule

A cascade isn't one reaction. It's three or four reactions stitched together so the product of step one becomes the substrate for step two — no isolation in between. The MacMillan team used a chiral tertiary amine to trigger an enantioselective organocascade: hydroamination, ring closure, and oxidation all happen in sequence inside a single flask.

The magic is the common intermediate. Their proposed mechanism (Figure in the Nature paper) shows how a simple acrylate and an indole derivative collapse into tetracyclic compound through three catalytic cycles. Once you've got that rigid, stereochemically defined scaffold, each alkaloid needs only five to nine additional steps — Heck coupling, selenium dioxide oxidation, or selective reduction, depending on the target.

Compare that to classical routes. The enantioselective synthesis of (−)-strychnine by Knight and Overman in required a dedicated multi-step sequence with no obvious shortcut to akuammicine or kopsinine. Here, the strychnine route takes twelve steps from the common scaffold; akuammicine needs only ten. Same starting material family. Different endpoints.

Why Six Molecules From One Scaffold Changes Drug Discovery Math

This is the angle I keep coming back to. Pharma doesn't buy one molecule — it buys a library of analogs and hopes one hits a target with acceptable pharmacokinetics. The traditional model: design ten syntheses, run them in parallel, pray three yield enough material for biological testing. Expensive. Slow. And it generates massive waste.

The collective synthesis model inverts the cost structure. You invest heavily upfront to validate one cascade sequence and one common intermediate. Then every downstream analog is comparatively cheap to make, because you skip the hardest stereochemical problems — they're already solved by the scaffold. The Nature paper demonstrates this with six alkaloids from *Strychnos* and *Kopsia* species, all sharing that tetracyclic core.

For Dutch researchers working in natural product chemistry — and there's a strong tradition here, with groups at Utrecht, Amsterdam, and Leiden focused on alkaloid bioactivity — this is directly relevant. If you can generate five structurally related indole alkaloids from one flask of compound , your hit rate in structure-activity relationship studies jumps without proportional increases in synthetic workload.

The Skeptical Take That the Paper Doesn't Address

I'll be honest. The elegance here is undeniable, but there's a gap between "six alkaloids from one scaffold" and "a platform for drug discovery." Strychnine is toxic. Akuammicine derivatives have been studied as anticancer agents. Kopsanone shows antitumor activity in cell lines. But none of these are approved drugs.

So the real question: does the cascade approach actually shorten lead optimization timelines? The paper shows synthetic feasibility — twelve steps to strychnine, ten to akuammicine. It doesn't show that you can generate analogs in a month with sufficient purity for pharmacokinetic profiling. That's where academic chemistry and industrial reality diverge.

And there's the scalability problem. The MacMillan group produced milligram quantities — enough for NMR characterization and biological assays. Pharma needs grams to kilograms for Phase I trials. Cascade reactions are notoriously sensitive to impurity profiles, solvent effects, and concentration. What works in a mL round-bottom flask may stall at L scale.

Who Actually Wins From This Breakthrough

Academic synthetic chemists. That's the obvious answer — this is a methods paper that opens new research avenues for groups specializing in alkaloid chemistry or asymmetric catalysis. The technique extends beyond these six compounds; any substrate capable of entering the cascade cycle becomes accessible.

But here's where it gets interesting for industry. CROs (contract research organizations) and academic-industry partnerships that specialize in natural product discovery now have a cheaper path to diverse analog sets. If you're running structure-activity studies on indole alkaloids, this approach cuts your synthetic budget by –% per compound after the initial scaffold is validated.

The losers? Traditional total synthesis groups whose expertise was building bespoke routes for single molecules. Their competitive advantage — deep knowledge of one molecule's synthetic history — matters less when a general platform can generate the same compound in fewer steps with comparable yield.

What This Means for the Next Decade of Natural Product Chemistry

I think we're going to see a shift from "one molecule, one synthesis" thinking toward platform-based approaches. The MacMillan work is an early proof of concept for what I'd call modular alkaloid chemistry — where the hard stereochemical problem (building the tetracyclic core) is solved once, and then you plug in different functional groups to explore biological space.

This connects directly to ongoing debates about whether AI-driven drug discovery will replace synthetic chemists. My take: no. But it changes what synthetic chemists do. Instead of designing routes molecule-by-molecule, they'll design cascades that generate families of molecules simultaneously. The skill set shifts from retrosynthetic analysis of single targets to cascade engineering for compound libraries.

If you're a researcher in the Netherlands working on natural products or asymmetric catalysis, this paper is worth reading not just for the chemistry but for the strategic implication: your next grant proposal might be stronger if you frame it around generating analog sets from common scaffolds rather than total synthesizing one molecule.

The Practical Details That Make or Break This Approach

Let's get specific. The cascade uses a chiral tertiary amine catalyst (typically a cinchona alkaloid derivative) to promote enantioselective hydroamination of an acrylate tethered to an indole. The key intermediate, compound , has four rings with defined stereochemistry at three or more centers. Getting there takes one catalytic step — that's the breakthrough.

From compound to strychnine: twelve steps. The critical operations include a Heck coupling (Pd-catalyzed), selenium dioxide oxidation of the tetrahydro-β-carboline, and final functional group manipulations. From compound to akuammicine: ten steps, with similar operations but different regioselectivity in the cyclization.

The yields matter. The Nature paper reports overall yields in the low single digits to mid-teens percent — respectable for complex molecule synthesis, but not spectacular. For drug discovery purposes, what matters more is consistency: can you reproduce these routes week after week with the same yield distribution? That's where industrial validation happens.

The Connection to Broader Trends in Health-Related Synthesis

This work sits at the intersection of organic chemistry and health science. Alkaloids like those synthesized here are active in antitumor, antiviral, and neuroprotective pathways. The ability to generate diverse analog sets rapidly accelerates structure-activity relationship studies that identify which molecular features correlate with biological efficacy.

There's a parallel trend in the broader research community: moving away from single-molecule total synthesis toward collective or platform approaches. Same logic applies to peptidomimetics, polyketides, and terpenoids — find the common scaffold that nature uses repeatedly, build it once, then branch out.

For Dutch chemists in particular — Wageningen's natural product isolation groups, Utrecht's synthetic methodology people — this cuts both ways. The upside: cheaper access to diverse alkaloid libraries for biological screening. The downside: you have to retrain chemists who think in bespoke syntheses to think like platform engineers instead.

My Take After Reading the Full Paper

I've read enough total synthesis papers to tell when something is genuinely new versus just incremental. This one lands in the first category. The organocascade approach isn't another asymmetric reaction — it's a design philosophy that treats molecular complexity as an engineering problem rather than an art form.

Now, the six alkaloids demonstrated here are all well-known. That's a weakness. It proves the method works for established structures but doesn't push into uncharted chemical space. The real test will be applying this cascade to novel natural products, or to designed molecules with no biosynthetic precedent.

But as a proof of concept? It's clean. Elegant. And strategically important for anyone in drug discovery who's tired of paying full price for every analog they need. If you work at the intersection of synthetic chemistry and health science, this is worth your time — not just to learn the cascade mechanism, but to rethink how you structure your research pipeline.

Where This Fits in the Broader Synthesis Literature

The MacMillan group's work builds on their earlier development of enantioselective organocascade catalysis (Huang et al., JACS ) and cycle-specific variants (Simmons et al., Angew. Chem. ). The Nature paper is the culmination: applying those methods to a real-world problem — making useful quantities of multiple natural products from one scaffold.

Compare this to other collective synthesis efforts. Grondal et al. reviewed organocatalytic cascade reactions in total synthesis (Nature Chem. ). Jones, Simmons, and MacMillan published a nine-step synthesis of (+)-minfiensine using similar cascades (JACS ). The current work extends the scope to six alkaloids with shared structural features.

The references section of the Nature paper is telling — it cites both classical strychnine syntheses (Knight & Overman ; Mori et al. ) and recent cascade methodology papers. That's a deliberate bridge between two eras of synthetic chemistry: the era of bespoke masterpieces and the emerging era of general platforms.

What Researchers Should Actually Do With This Information

If you're a graduate student or postdoc in organic chemistry: learn the cascade mechanism. Understand why the chiral amine selects one enantiomer over the other. Be able to draw compound and explain how each alkaloid diverges from that point. That's your competitive advantage when applying for positions at pharma companies or CROs.

If you're a PI running a natural product lab: ask whether your current projects would benefit from a platform approach. Can you identify three or more targets that share a common scaffold? If yes, invest in developing one cascade sequence rather than three separate syntheses.

If you're in industry drug discovery: look at your hit-to-lead pipeline. Are you paying full synthetic cost for every analog? The MacMillan approach suggests that –% of those costs might be avoidable if you reorganize around common scaffolds rather than individual molecules.

The One Thing Most Readers Will Miss About This Paper

Everyone focuses on the six alkaloids. But the real breakthrough is in Figure — the proposed mechanism for generating compound from a simple acrylate-indole starting material through three catalytic cycles. That's not just a reaction sequence; it's a design principle.

The principle: if you can identify the minimal structural features that a class of natural products share (in this case, the tetracyclic indole core), and build those features using catalytic cascades rather than step-by-step construction, then every member of that class becomes accessible at lower cost.

And that principle generalizes. It applies to polyketides with shared macrolactone cores. It applies to terpenoids with common ring systems. It applies to alkaloids from entirely different plant families that happen to converge on similar tetracyclic architectures.

Final Thoughts for the Dutch Scientific Community

The Netherlands has a strong tradition in natural product chemistry — from alkaloid isolation at Wageningen to synthetic methodology at Utrecht and Amsterdam. This paper represents exactly the kind of work that strengthens those traditions: it's methodologically rigorous, strategically important, and directly applicable.

My advice: don't just read this paper. Implement the cascade in your lab. Generate five or six alkaloids from compound and run them through your biological assays. The data you get will be worth more than any grant application that merely cites the MacMillan work.

The future of natural product chemistry isn't one molecule at a time. It's families of molecules from shared scaffolds. The MacMillan team showed us how to build the scaffold once and then branch out efficiently. That's not just better science — it's smarter science.